Stocklytics Platform
Asset logo for symbol VVOS
Vivos Therapeutics
VVOS58
$2.65arrow_drop_down1.48%-$0.04
Penny Stock
Asset logo for symbol VVOS
VVOS58

$2.65

arrow_drop_down1.48%
Key Stats
Open$2.71
Prev. Close$2.69
EPS-6.80
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$12.81M
PE Ratio-
LOWHIGH
Day Range2.66
2.71
52 Week Range0.24
48.79
Ratios
Revenue-
EPS-6.80
Fundamentals
Payout Ratio-
Industry average yield2.93%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

VVOS-
US Healthcare Sector-
US Market-
check_circle

VVOS / Market

VVOS exceeded the US Market which returned 0.36% over the last twenty four hours.
check_circle

VVOS / Healthcare Sector

VVOS exceeded the US Healthcare sector which returned 3.77% over the last twenty four hours.

Vivos Therapeutics (VVOS) Statistics

Vivos Therapeutics, Inc. (VVOS) is a company focused on providing innovative solutions for the treatment of obstructive sleep apnea (OSA) and other breathing disorders. The company's flagship product, the Vivos System, is a non-surgical, non-pharmaceutical treatment option that aims to address the underlying causes of OSA. By enhancing the size and shape of the patient's upper airway, the Vivos System can help alleviate the symptoms of OSA and improve overall sleep quality. With an estimated 54 million Americans suffering from OSA, there is a significant market opportunity for Vivos Therapeutics to tap into.
When it comes to valuation metrics, Vivos Therapeutics, Inc. (VVOS) appears to be trading at a premium compared to its peers. The company has a market capitalization of $XXX million and an enterprise value of $XXX million, which gives it a price-to-sales ratio of XX.XX. This suggests that investors are willing to pay a higher price for each dollar of revenue generated by Vivos Therapeutics. However, it's worth noting that the company is still in the early stages of commercialization, so its revenue per share is currently relatively low. As the company continues to grow its customer base and generate more sales, this metric should improve over time.
add Vivos Therapeutics to watchlist

Keep an eye on Vivos Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Vivos Therapeutics (VVOS) stock's performance compared to its sector and the market over the past year?

Over the past year, Vivos Therapeutics (VVOS) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 30.03%, Vivos Therapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 71.30%, it has fallen short of the market average. This comparison highlights Vivos Therapeutics's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Vivos Therapeutics (VVOS) stock?

The PE ratio for Vivos Therapeutics (VVOS) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Vivos Therapeutics (VVOS) stock?

The Earnings Per Share (EPS) for Vivos Therapeutics (VVOS), calculated on a diluted basis, is -$6.8. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Vivos Therapeutics (VVOS) stock?

The operating margin for Vivos Therapeutics (VVOS) is -47.76%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Vivos Therapeutics (VVOS) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Vivos Therapeutics (VVOS) is -$12.9M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Vivos Therapeutics (VVOS) have?

Vivos Therapeutics (VVOS) has a total debt of $1.76M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$5.14M.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level